Comparison of the effects of carvedilol and nebivolol on diastolic functions of the left ventricle in patients with non-ischemic heart failure

Doğan, Abdullah; Karabacak, Mustafa; Tayyar, Senol; Erdoğan, Doğan; Özaydın, Mehmet

doi:10.5603/cj.a2013.0062

Cited by 10 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistently, Nebivolol has been reported to mitigate the expressions/activities of MMP-2 and MMP-9 (Ceron et al 2013). In this study, Nevibolol was used at the concentrations of 1, 5, and 10 μM, which are consistent with previous studies showing that Nebivolol exerts various pharmacological actions in a range of micromolar concentrations and are comparable to the concentrations used for treatment of patients (Dogan et al 2014). Consistently, it was shown that increasing amounts of the Nevibolol (from 1 to 25 μM) increased the production of nitric oxide and reduced the generation of ROS in endothelial cells (Cominacini et al 2003).…”

Section: Discussionsupporting

confidence: 86%

Protective effects of Nebivolol against interleukin-1β (IL-1β)-induced type II collagen destruction mediated by matrix metalloproteinase-13 (MMP-13)

Zhao

Wang

et al. 2017

Cell Stress and Chaperones

View full text Add to dashboard Cite

The pathological progression of osteoarthritis (OA) involves degradation of articular cartilage matrix. Type II collagen is the main component of cartilage matrix, which is degraded by pro-inflammatory cytokines such as IL-1β mediated by MMP-13. Nebivolol, a licensed drug used for the treatment of hypertension in clinics, displays its anti-inflammatory capacity in various conditions. However, whether Nebivolol has a protective effect on cartilage matrix degradation has not been reported before. In this study, we investigated the effects of Nebivolol on regulating the expression of MMP-13 and degradation of type II collagen. Our results indicate that Nebivolol alleviated the increase in gene expression, protein expression, and activity of MMP-13 induced by IL-1β. Importantly, IL-1β strikingly reduced the levels of type II collagen in cell culture supernatants, which was reversed by treatment with Nebivolol in a dose-dependent manner. Mechanistically, Nebivolol was found to alleviate the increased levels of phosphorylated IκBα and reduced levels of total IκBα induced by IL-1β, which subsequently mitigated p65 nuclear translocation and the transcriptional activity of NF-κB. Furthermore, our results indicated that IL-1β treatment resulted in a significant increase in expression of the transcriptional factor interferon regulatory factor-1 (IRF-1) at both the mRNA and protein levels, which was significantly ameliorated by treatment with Nebivolol. The combination of these findings suggests that Nebivolol can potentially be applied in human OA treatment.

show abstract

Section: Discussionsupporting

confidence: 86%

Protective effects of Nebivolol against interleukin-1β (IL-1β)-induced type II collagen destruction mediated by matrix metalloproteinase-13 (MMP-13)

Zhao

Wang

et al. 2017

Cell Stress and Chaperones

View full text Add to dashboard Cite

show abstract

“…Some findings of this study on the effects of both agents on diastolic LV function were previously published elsewhere (17). Thus, the patient characteristics and laboratory and echocardiography findings were similar to those of the previously published study.…”

Section: Methodsmentioning

confidence: 57%

“…Thereafter, carvedilol or nebivolol was randomly started, and they were up-titrated as previously reported elsewhere (17). After the target or maximum tolerable dose, patients were evaluated in the outpatient clinic at the first, third, and sixth months.…”

Section: Methodsmentioning

confidence: 99%

Carvedilol and nebivolol improve left ventricular systolic functions in patients with non-ischemic heart failure

Karabacak¹,

Doğan²,

Tayyar³

et al. 2015

Anatol J Cardiol

Self Cite

View full text Add to dashboard Cite

Objective:It is unclear whether carvedilol and nebivolol produce different effects on short-term left ventricle (LV) systolic function in heart failure (HF). These drugs could improve systolic and diastolic functions of the LV. Thus, we aimed to compare their effects on LV systolic functions in patients with non-ischemic HF.Methods:This study included 61 symptomatic non-ischemic HF patients with low ejection fraction (EF) (EF≤40%) between September 2008 and November 2010. The patients were randomized to carvedilol (n=31, 16 males) or nebivolol (n=30, 19 male). They were evaluated clinically and echocardiographically at baseline and 3 and 6 months after target dose; 42% of patients in the carvedilol group and 47% in the nebivolol group achieved the target dose before randomization. LV systolic functions were evaluated with ventricle diameters, EF, ejection time (ET), isovolumic contraction time (IVCT), isovolumic relaxation time (IVRT), and myocardial performance index (MPI).Results:At 6 months, carvedilol and nebivolol similarly improved EF (from 33±4% to 36±5%, p<0.01 and from 34±5% to 37±5%, p<0.01, inter-group p=0.30, respectively) and MPI (from 0.71±0.10 to 0.53±0.07, p<0.01 and from 0.69±0.13 to 0.52±0.08, p<0.01, intergroup p=0.45, respectively). LV diameter was reduced by a similar extent in both groups. In each group, IVCT and IVRT were significantly shortened and ET was prolonged, but there was no inter-group difference. Functional capacity improved similarly (from NYHA Class II-III to Class I-0) in both groups, as did heart rate and blood pressure. Reduction of pro-B-type natriuretic peptide levels was also comparable in both groups (p=0.41).Conclusion:Carvedilol and nebivolol can similarly improve LV systolic functions in non-ischemic HF patients.

show abstract

“…At present, little data are available on the comparative effectiveness of carvedilol and nebivolol for HF. A recent study found that carvedilol and nebivolol appear to similarly improve LV diastolic functions in nonischemic HF patients [25]. However, that study did not involve an HF population with preserved EF.…”

Section: Discussionmentioning

confidence: 99%

Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial

Park

2016

Trials

View full text Add to dashboard Cite

BackgroundHeart failure (HF) is a common and disabling condition in older people. Randomized clinical trials and meta-analyses have clearly demonstrated that the long-term use of β-Blockers improves the outcome of patients with HF. However, limited data are available on the treatment of older HF patients with preserved ejection fraction (EF). No study has specifically compared the relative effectiveness of carvedilol and nebivolol in treating HF in older patients with preserved EF.Method/designThis trial is a prospective, randomized, open-label, single-centre, active controlled study designed to investigate the effects of nebivolol and carvedilol on diastolic function of the left ventricle (LV) in older HF patients with preserved EF.We will test the hypothesis that nebivolol improves LV diastolic function to a greater extent than carvedilol in patients over 70 years of age. The study population includes 62 older patients newly diagnosed with HF. Patients will be included in the study if they have a LVEF ≥40 %, New York Heart Association (NYHA) functional classes I, II or III status, and have been clinically stable without hospital admission for HF in the preceding 3 months. Eligible patients will be randomly assigned, in a 1:1 ratio, to receive a loading and maintenance dose of either nebivolol or carvedilol. Echocardiographic evaluations will be performed at baseline, 6, and 12 months after therapy. Clinical assessment and laboratory tests are to be performed at fixed times.DiscussionThis trial is a single-center study that aims to evaluate the impact of nebivolol on LV diastolic function. The results of the study will provide information about the optimal choice of a β-Blocker in the management of patients after diagnosis of HF with preserved EF. The results will be available by 2017.Trial registrationClinicalTrials.gov Identifier: NCT02619526, registered on 25 November 2015.Electronic supplementary materialThe online version of this article (doi:10.1186/s13063-016-1656-y) contains supplementary material, which is available to authorized users.

show abstract

Comparison of the effects of carvedilol and nebivolol on diastolic functions of the left ventricle in patients with non-ischemic heart failure

Cited by 10 publications

References 29 publications

Protective effects of Nebivolol against interleukin-1β (IL-1β)-induced type II collagen destruction mediated by matrix metalloproteinase-13 (MMP-13)

Protective effects of Nebivolol against interleukin-1β (IL-1β)-induced type II collagen destruction mediated by matrix metalloproteinase-13 (MMP-13)

Carvedilol and nebivolol improve left ventricular systolic functions in patients with non-ischemic heart failure

Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial

Contact Info

Product

Resources

About